5mg/片，60片/盒。 【禁忌症】 无。 【警告和预防措施】 • 已经观察到高血压，包括高血压危象。在开始使用LuciAxi之前，应控制好血压。监测高血压并根据需要进行治疗。对于使用抗高血压药物后仍持续高血压的患者，减少LuciAxi剂量。

2024年8月14日 · Apixaban is used to lower the risk of stroke caused by a blood clot in people with a heart rhythm disorder called atrial fibrillation. Apixaban is also used after hip or knee replacement surgery to prevent a type of blood clot called deep vein thrombosis (DVT), which can lead to blood clots in the lungs (pulmonary embolism).

KEYNOTE-426研究(NCT02853331)是一项随机、开放标签、3期试验，在首个中期分析中，一线治疗帕博利珠单抗（pembro）+阿昔替尼（axi）显示，与舒尼替尼（sun）相比，晚期ccRCC的OS、PFS和ORR具有统计学意义。

2022年6月7日 · 肾癌围手术期治疗一直是临床研究的热点，2021年ASCO会议公布的KEYNOTE564研究证实了免疫治疗在高危肾癌术后辅助治疗取得成功，本次会议除了该项临床研究数据更新以外，还有依维莫司用于肾癌术后辅助治疗的Ⅲ期研究（EVEREST，SWOG S0931）结果的公布。 1.依维莫司未能改变靶向药物辅助治疗失败的命运. SWOG S0931研究是将依维莫司用于中高危肾癌术后辅助治疗的随机对照III期研究，主要研究终点为无复发生存期（RFS），这 …

2018年6月1日 · Axitinib (Axi) is a VEGF-R inhibitor with prior clinical data supporting increased efficacy with dose titration. The existing titration schema of 5mg BID to 7mg BID to 10mg BID every 4 weeks, however, can lead to toxicity due to the magnitude of dose increases.

2025年2月18日 · Most patients (95%; n=285) started AXI at the initial recommended dose of 5 mg twice daily (BID; Table). Few patients (14.3%; n=43) required AXI dose reductions, with a median time to first AXI dose reduction of 2.3 months (IQR: 1.4-3.7), while 8.7% (n=26) of patients were able to dose escalate (7.3% [n=22] to 7 mg BID; 1.3% [n=4] to 10 mg BID).

2023年6月7日 · Methods: Adults with confirmed locally advanced or metastatic ccRCC with or without sarcomatoid features, no previous systemic therapy for metastatic ccRCC, KPS ≥70%, and ≥1 lesion measurable per RECIST v1.1 were randomly assigned 1:1 to receive pembro 200 mg IV Q3W for 35 doses (~2 y) + axi 5 mg PO BID or sun 50 mg PO QD on a 4-wk-on/2-wk ...

The starting dose of axitinib was 5 mg twice daily, with a possibility of titration to 7 mg twice daily, and then 10 mg twice daily as per the previously described criteria in the AXIS trial. The fixed dose of sorafenib remained stable during the treatment, at 400 mg twice a day.

Keynote-426研究结果更新Keynote-426研究中期报告显示了Pembrolizumab+Axitinib的组合作为一线治疗方案显著改善了转移性肾癌患者的预后。 此次报告更新结果。 上海交通大学医学院附属仁济医院泌尿科孔文研究设计：Pembro+Axi组： Pembro 200mg IV Q3w 共35剂，Axi 5mg po Bid Sunitinib组：50mg po Qd 4w/2w结果：Pembro+Axi在IMDC各个风险亚组和不同PD-L1表达水平组中都有临床获益；事后分析提示Pembro+Axi组靶病灶减小达到80%的患者可能与CR患者获得 …

2020年5月15日 · 结论：帕博利珠单抗+阿昔替尼用于aRCC患者的一线治疗，在中位随访时间为27个月时，相对于舒尼替尼持续表现出更佳的抗肿瘤活性。 编辑丨中国医学论坛报 佑明. 2020年美国临床肿瘤学会（ASCO）年会将采用线上会议的模式，如期将于美国东部时间5月29日~5月31日召开。 全世界的临床肿瘤学专家，也有了全球“云端”学术交流的新体验。 中国医学论坛报社也将紧跟会议节奏，开启“2020ASCO壹生学术节”！ 携手中国临床肿瘤学会（CSCO）将第壹现场搬 …

Co-stimulatory PFOX activates exhausted T-cells, and dendritic cells and increases proliferation, effector function, and survival of T cells. We hypothesized that PFOX + Axi would improve progression free survival (PFS) vs. Axi in patients (pts) with mRCC after IO Tx.

Here, we report long-term efficacy and safety data of the combination AXI/pembro from the Phase 1 trial, with almost 5 years of follow-up. Methods: 52 treatment-naïve patients with advanced RCC were enrolled between 23 September 2014 and 13 October 2015, and were treated with oral AXI 5 mg twice daily and intravenous pembro 2 mg/kg every 3 ...

Co-stimulatory PFOX activates exhausted T-cells, and dendritic cells and increases proliferation, effector function, and survival of T cells. We hy-pothesized that PFOX + Axi would improve progression free survival (PFS) vs. Axi in patients (pts) with mRCC after IO Tx.

2024年7月25日 · 5 mg orally 2 times a day Use: Reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Adult Dose for Deep Vein Thrombosis:

Axitinib (Axi) is an orally available tyrosine kinase inhibitor which is approved for the treatment of metastatic renal cell carcinoma. It has a high affinity and specificity for vascular endothelial growth factor receptors, thereby acting similar to Bev.

2023年2月21日 · In 11% of pts a starting dose of Axi <5mg was reported (8% higher starting dose). 2% of pts experienced Axi dose titration while 37% of pts had a dose reduction. Pts completed a mean of 10 (1 - 31) cycles of Pembro. Toxicity led to treatment discontinuation in 20% (7/35) of cases.

We report long-term efficacy and safety of the axitinib/pembrolizumab from the phase I trial (NCT02133742), after 46-55 months from study initiation (data cut-off date, 23rd July 2019). Methods: Fifty-two treatment-naïve patients with advanced RCC were treated with oral axitinib 5 mg twice daily and intravenous pembrolizumab 2 mg/kg every 3 weeks.

2023年2月20日 · In 11% of pts a starting dose of Axi <5mg was reported (8% higher starting dose). 2% of pts experienced Axi dose titration while 37% of pts had a dose reduction. Pts completed a mean of 10 (1 -...

Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC). Sarmad Sadeghi, Rahul Atul Parikh, Denice D. Tsao-Wei, Susan G. Groshen, Ming Li, Leonard Joseph Appleman, Scott T. Tagawa, David M. Nanus, Ana M. Molina, Cheryl ...

Background: In KEYNOTE-426, pembro + axi significantly improved OS (HR 0.53, P < .0001), PFS (HR 0.69, P = .0001), and ORR (59.3% vs 35.7%, P < .0001) vs sunitinib and had manageable toxicity as first-line therapy for mRCC (NCT02853331). The pembro + axi benefit was observed across all IMDC risk groups and regardless of PD-L1 expression. We present data for the combined intermediate/poor risk ...